Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SET domain containing 3, actin N3-histidine methyltransferase (SETD3) is an evolutionarily conserved enzyme responsible for the methylation of histidine 73 (H73) of β-actin by transferring a methyl group from S-adenosyl-L-methionine (AdoMet/SAM) to the imidazole ring of actin[1][5][3]. This modification is crucial for maintaining actin filament stability and cytoskeletal integrity[1][5]. Structurally, SETD3 possesses a catalytic SET domain and a RuBisCO LSMT substrate-binding domain, providing specificity for actin and potentially other protein substrates[5]. Initially thought to act on histones, current evidence supports actin H73 as its primary physiological substrate[5][3]. Beyond cytoskeletal roles, SETD3 also impacts cell cycle, apoptosis, smooth muscle contractility, and has been implicated as a host factor in enterovirus replication[3][5][8]. Loss of SETD3 leads to cytoskeletal alterations, increased glycolytic activity, and impaired smooth muscle contraction, and may contribute to tumorigenesis and resistance to viral infection[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SET domain containing 3, actin N3-histidine methyltransferase (SETD3).